Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Antineoplastic Agents. Found 201 abstracts

paginate
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet (London, England). 2019 Jan 05;393(10166):40-50.   PMCID: PMC6541928
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algul H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. The New England journal of medicine. 2019 Jul 25;381(4):317-27.   PMCID: PMC6810605
Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019 Mar 21;380(12):1116-27.
Chang WL, Jackson C, Riel S, Cooper HS, Devarajan K, Hensley HH, Zhou Y, Vanderveer LA, Nguyen MT, Clapper ML. Differential preventive activity of sulindac and atorvastatin in Apc(+/Min-FCCC)mice with or without colorectal adenomas. Gut. 2018 Jul;67(7):1290-8.   PMCID: PMC6031273
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DP, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine. 2018 Feb 22;378(8):731-9.   PMCID: PMC5857389
Galal Osman A, Elokely KM, Yadav VK, Carvalho P, Radwan M, Slade D, Gul W, Khan S, Dale OR, Husni AS, Klein ML, Cutler SJ, Ross SA, ElSohly MA. Bioactive products from singlet oxygen photooxygenation of cannabinoids. European journal of medicinal chemistry. 2018 Jan;143:983-96.
Gerson JN, Ramamurthy C, Borghaei H. Managing adverse effects of immunotherapy. Clinical advances in hematology & oncology : H&O. 2018 May;16(5):364-74.   PMCID: Review
Geynisman DM, Meeker CR, Doyle JL, Handorf EA, Bilusic M, Plimack ER, Wong YN. Provider and patient burdens of obtaining oral anticancer medications. The American journal of managed care. 2018 Apr;24(4):e128-e133.
Ghatalia P, Zibelman MR, Geynisman DM, Plimack ER. Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma. Clinical advances in hematology & oncology : H&O. 2018 Oct;16(10):677-86.
Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018 Jun;21(6):742-7.
Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O'Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value Health. 2018 Jun;21(6):742-7.
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European urology focus. 2018 Dec;4(6):937-45.   PMCID: PMC5626651
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJ, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, CheckMate I. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. The New England journal of medicine. 2017 Jun 22;376(25):2415-26.   PMCID: Comment
de Oliveira JF, Lima TS, Vendramini-Costa DB, de Lacerda Pedrosa SC, Lafayette EA, da Silva RM, de Almeida SM, de Moura RO, Ruiz A, de Carvalho JE, de Lima M. Thiosemicarbazones and 4-thiazolidinones indole-based derivatives: Synthesis, evaluation of antiproliferative activity, cell death mechanisms and topoisomerase inhibition assay. European journal of medicinal chemistry. 2017 Aug 18;136:305-14.
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhaeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crino L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WE. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017 Dec 10;35(35):3924-33.   PMCID: PMC6075826
Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CA, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM. Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. Cancer. 2017 Jul;123(13):2489-96.   PMCID: PMC5474197
Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports. 2017 Apr;19(4):27.   PMCID: Review
Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr;35(10):1112-8.   PMCID: PMC5559878
Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017 Jul;58:70-6.   PMCID: Review
Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Apr;3(4):483-91.   PMCID: PMC5470422
Borghaei H, Brahmer J. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer [comment]. The New England journal of medicine. 2016 Feb 04;374(5):493-4.   PMCID: NA
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 Oct;14(10):1213-24.   PMCID: PMC5379654
Czyz M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. Oncotarget. 2016 Nov 15;7(46):75551-60.   PMCID: PMC5342760
Dasgupta Y, Koptyra M, Hoser G, Kantekure K, Roy D, Gornicka B, Nieborowska-Skorska M, Bolton-Gillespie E, Cerny-Reiterer S, Muschen M, Valent P, Wasik MA, Richardson C, Hantschel O, van der Kuip H, Stoklosa T, Skorski T. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 Apr 28;127(17):2131-43.   PMCID: PMC4850868
Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 Mar;14(3):255-64.
George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. JAMA Oncol. 2016 Sep;2(9):1179-86.   PMCID: PMC5568541
Geynisman DM, Wong YN. Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients?. JAMA Oncol. 2016 Mar;2(3):295-6.
Geynisman DM, Wong YN. Drug Supply Chain Security Act and Oral Anticancer Medications: Are We Shortchanging Our Patients?. JAMA Oncol. 2016 Mar;2(3):295-6.
Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 May;22(9):2146-54.
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16.   PMCID: PMC4878938
Huang F, Goyal N, Sullivan K, Hanamshet K, Patel M, Mazina OM, Wang CX, An WF, Spoonamore J, Metkar S, Emmitte KA, Cocklin S, Skorski T, Mazin AV. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic acids research. 2016 May 19;44(9):4189-99.   PMCID: PMC4872086
Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan;22(1):34-43.
Winn JS, Baker MG, Fanous IS, Slack-Davis JK, Atkins KA, Dillon PM. Lobular Breast Cancer and Abdominal Metastases: A Retrospective Review and Impact on Survival. Oncology. 2016 Jan;91(3):135-42.
Zibelman M, Plimack ER. Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm. Oncology (Williston Park). 2016 Feb;30(2):160-2, 176.
Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015 May;14(1):99.   PMCID: 4428111
Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer Res. 2015 Apr 15;75(8):1668-74.   PMCID: PMC4541796
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine. 2015 Jan 22;372(4):311-9.   PMCID: 4348009
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England journal of medicine. 2015 Oct 22;373(17):1627-39.
Burness ML, Obeid EI, Olopade OI. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr;15(2):e155-8.
Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I, Sharma D, Saxena NK, Singh N, Vlachostergios PJ, Guo S, Honoki K, Fujii H, Georgakilas AG, Bilsland A, Amedei A, Niccolai E, Amin A, Ashraf SS, Boosani CS, Guha G, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Azmi AS, Bhakta D, Halicka D, Keith WN, Nowsheen S. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Semin Cancer Biol. 2015 Dec;35 Suppl:S25-54.   PMCID: PMC4898971
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr;21(7):1566-73.
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams S. CTLA-4 blockade synergizes therapeutically with PARP-inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015 Jul 02;3(11):1257-68.   PMCID: 4984269
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2015 Nov 05;373(19):1803-13.
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May;33(13):1430-7.   PMCID: PMC4806782
Najjar M, Suebsuwong C, Ray S, Thapa R, Maki J, Nogusa S, Shah S, Saleh D, Gough P, Bertin J, Yuan J, Balachandran S, Cuny G, Degterev A. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Reports. 2015 Mar 24;10(11):1850-60.   PMCID: 4494889
Peethambaram PP, Hartmann LC, Jonker DJ, de Jonge M, Plummer ER, Martin L, Konner J, Marshall J, Goss GD, Teslenko V, Clemens PL, Cohen LJ, Ahlers CM, Alland L. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
Plimack ER, Dunbrack RL, Brennan TA, Andrake MD, Zhou Y, Serebriiskii IG, Slifker M, Alpaugh K, Dulaimi E, Palma N, Hoffman-Censits J, Bilusic M, Wong YN, Kutikov A, Viterbo R, Greenberg RE, Chen DY, Lallas CD, Trabulsi EJ, Yelensky R, McConkey DJ, Miller VA, Golemis EA, Ross EA. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol. 2015 Dec;68(6):959-67.   PMCID: PMC4764095
Pogash TJ, El-Bayoumy K, Amin S, Gowda K, de Cicco RL, Barton M, Su Y, Russo IH, Himmelberger JA, Slifker M, Manni A, Russo J. Oxidized derivative of docosahexaenoic acid preferentially inhibit cell proliferation in triple negative over luminal breast cancer cells. In Vitro Cell Dev Biol Anim. 2015 Feb;51(2):121-7.   PMCID: 4948656
Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, Testa JR, Kimura T. Preclinical efficacy for AKT targeting in clear cell carcinoma of the ovary. Molecular Cancer Research. 2015 Apr;13(4):795-806.   PMCID: PMC4398602
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015 Aug 20;373(8):737-46.   PMCID: 4562797
Talekar MK, Allen JE, Dicker DT, El-Deiry WS. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell cycle (Georgetown, Tex). 2015 Aug;14(15):2422-8.   PMCID: PMC4614396
Wong SJ, Moughan J, Meropol NJ, Anne PR, Kachnic LA, Rashid A, Watson JC, Mitchell EP, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. Efficacy Endpoints of Radiation Therapy Group Protocol 0247: A Randomized, Phase 2 Study of Neoadjuvant Radiation Therapy Plus Concurrent Capecitabine and Irinotecan or Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer. International Journal of Radiation Oncology Biology Physics. 2015 Jan;91(1):116-23.   PMCID: 4385459
Wuthrick EJ, Zhang Q, Machtay M, Rosenthal DI, Nguyen-Tan PF, Fortin A, Silverman CL, Raben A, Kim HE, Horwitz EM, Read NE, Harris J, Wu Q, Le QT, Gillison ML. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol. 2015 Jan 10;33(2):156-64.   PMCID: PMC4279235
Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. Lancet Oncol. 2015 Oct;16(13):e510-21.
Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM. A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite. Clin Genitourin Cancer. 2015 Apr;13(2):142-9.
Barta SK, Xue X, Wang D, Lee JY, Kaplan LD, Ribera JM, Oriol A, Spina M, Tirelli U, Boue F, Wilson WH, Wyen C, Dunleavy K, Noy A, Sparano JA. A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica. 2014 Nov;99(11):1731-7.   PMCID: 4222464
Goldsack JC, Reilly C, Bush C, McElligott S, Bristol MN, Motanya UN, Field R, Vozniak JM, Wong YN, Schwartz JS, Domchek S. Impact of shortages of injectable oncology drugs on patient care. Am J Health Syst Pharm. 2014 Apr;71(7):571-8.
Haluska P, Menefee M, Plimack ER, Rosenberg J, Northfelt D, LaVallee T, Shi L, Yu XQ, Burke P, Huang J, Viner J, McDevitt J, LoRusso P. Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumors. Clin Cancer Res. 2014 Sep 15;20(18):4747-57.   PMCID: 4377301
Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, Cohen RB. Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2014 Oct;32(28):3103-10.
Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR. HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells. Cancer Res. 2014 Feb 15;74(4):1128-40.   PMCID: 4353573
Murray JC, Aldeghaither D, Wang S, Nasto RE, Jablonski SA, Tang Y, Weiner LM. c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunol Res. 2014 Dec;2(12):1186-98.   PMCID: 4258447
Plimack ER, Tan T, Wong YN, von Mehren MM, Malizzia L, Roethke SK, Litwin S, Li T, Hudes GR, Haas NB. A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. The oncologist. 2014 Apr;19(4):354-5.   PMCID: Pmc3983829
Shen C, Chien CR, Geynisman DM, Smieliauskas F, Shih YC. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb;14(1):45-69.
Sodani K, Patel A, Anreddy N, Singh S, Yang DH, Kathawala RJ, Kumar P, Talele TT, Chen ZS. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochemical pharmacology. 2014 May;89(1):52-61.   PMCID: Pmc3983711
Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR. Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. Clin Genitourin Cancer. 2014 Dec;12(6):395-8.
Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma therapy. Journal of hematology & oncology. 2014 Sep;7:58.   PMCID: 4172963
Tomaszewski JJ, Handorf E, Corcoran AT, Wong YN, Mehrazin R, Bekelman JE, Canter D, Kutikov A, Chen DY, Uzzo RG, Smaldone MC. Care transitions between hospitals are associated with treatment delay for patients with muscle invasive bladder cancer. J Urol. 2014 Nov;192(5):1349-54.   PMCID: PMC4422495
Vijayvergia N, Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Sep;74(3):437-46.
von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.   PMCID: Pmc4045341
Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget. 2014 Dec 30;5(24):12728-37.   PMCID: PMC4350349
Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 06;123(6):837-42.   PMCID: PMC5527396
Boland PM, Burtness B. Esophageal carcinoma: are modern targeted therapies shaking the rock?. Curr Opin Oncol. 2013 Jul;25(4):417-24.   PMCID: No NIH funding
Golovine KV, Makhov PB, Teper E, Kutikov A, Canter D, Uzzo RG, Kolenko VM. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells. The Prostate. 2013 Jan;73(1):23-30.   PMCID: PMC3491117
Kotredes KP, Gamero AM. Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res. 2013 Apr;33(4):162-70.   PMCID: Pmc3624694
Movva S. Emerging therapies for sarcoma. Curr Probl Cancer. 2013 Mar;37(2):87-101.   PMCID: Review
Vadakara J, von Mehren M. Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies. Hematol Oncol Clin North Am. 2013 Oct;27(5):905-20.   PMCID: Pmc3792495
Ratushny V, Pathak HB, Beeharry N, Tikhmyanova N, Xiao F, Li T, Litwin S, Connolly DC, Yen TJ, Weiner LM, Godwin AK, Golemis EA. Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene. 2012 Mar 08;31(10):1217-27.   PMCID: PMC3204164
Canter D, Viterbo R, Kutikov A, Wong YN, Plimack E, Zhu F, Oblaczynski M, Berberian R, Chen DY, Greenberg RE, Uzzo RG, Boorjian SA. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology. 2011 Jan;77(1):160-5.   PMCID: publisher will deposit
Dees EC, Infante JR, Cohen RB, O'Neil BH, Jones S, von Mehren M, Danaee H, Lee Y, Ecsedy J, Manfredi M, Galvin K, Stringer B, Liu H, Eton O, Fingert H, Burris H. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Apr;67(4):945-54.   PMCID: PMC3026871
Held-Warmkessel J. Taming three high-risk chemotherapy complications. Nursing. 2011 Nov;41(11):30-7.   PMCID: not NIH funded
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a conventional low neck field (LNF) and intensity-modulated radiotherapy (IMRT): no clinical detriment of IMRT to an anterior LNF during the treatment of head-and neck-cancer. Int J Radiat Oncol Biol Phys. 2011 Jan;79(1):65-70.   PMCID: PMC3339153
von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?. Cancer Treat Rev. 2011 Jun;37(4):291-9.   PMCID: not NIH funded
Altomare DA, Rybak SM, Pei J, Maizel JV, Cheung M, Testa JR, Shogen K. Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent. BMC cancer. 2010 Jan;10:34.   PMCID: PMC2829496
Cukierman E, Khan DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochemical pharmacology. 2010 Sep;80(5):762-70.   PMCID: PMC2897922
Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU international. 2010 Jul;106(2):218-23.   PMCID: PMC2906619
Freedman GM, Li T, Nicolaou N, Chen Y, Ma CC, Anderson PR. Breast intensity-modulated radiation therapy reduces time spent with acute dermatitis for women of all breast sizes during radiation. Int J Radiat Oncol Biol Phys. 2009 Jul;74(3):689-94.   PMCID: PMC2720600
Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon RM, Blum D, Ubel PA, Schnipper LE, American Society of Clinical O. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009 Aug 10;27(23):3868-74.
Pimkina J, Murphy ME. ARF, autophagy and tumor suppression. Autophagy. 2009 Apr;5(3):397-9.   PMCID: PMC2667648
Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol. 2009 Apr;113(1):21-7.   PMCID: PMC 2741166
von Mehren M, Watson JC. Perioperative tyrosine kinase inhibitors for GIST: standard ... or an idea that needs further investigation?. Oncology (Williston Park). 2009 Jan;23(1):65-6.   PMCID: PMC 2861343
Wong YN, Meropol NJ, Speier W, Sargent D, Goldberg RM, Beck JR. Cost implications of new treatments for advanced colorectal cancer. Cancer. 2009 May 15;115(10):2081-91.   PMCID: PMC2875773
Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008 Jan;6 Suppl 4:S1-S25; quiz S26-S27.
Cioc AM, Vanderwerf SM, Peterson BA, Robu VG, Forster CL, Pambuccian SE. Rituximab-induced changes in hematolymphoid tissues found at autopsy. American journal of clinical pathology. 2008 Oct;130(4):604-12.
Held-Warmkessel J. Caring for a patient with metastatic prostate cancer. Nursing. 2008 Jun;38(6):52-6.
Held-Warmkessel J. Targeted cancer. These "smart weapons" hit cancer in novel ways. Nursing. 2008 Sep;38(9):26-32.
Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD, National Comprehensive Cancer N. Hodgkin disease/lymphoma. J Natl Compr Canc Netw. 2008 Jul;6(6):594-622.
Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30.
Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?. Clinical lung cancer. 2008 Mar;9(2):85-91.
Mehra R, Cohen RB. New agents in the treatment for malignancies of the salivary and thyroid glands. Hematol Oncol Clin North Am. 2008 Dec;22(6):1279-95, xi.   PMCID: PMC2659655
Mehra R, Cohen RB, Harari PM. EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Current oncology reports. 2008 Mar;10(2):176-84.
Ozols RF. Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer. Advances in experimental medicine and biology. 2008 Jan;622:131-43.
Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P. Speeding up the evaluation of new agents in cancer. Journal of the National Cancer Institute. 2008 Sep 03;100(17):1204-14.   PMCID: PMC2528020
Patel BB, He YA, Li XM, Frolov A, Vanderveer L, Slater C, Schilder RJ, von Mehren M, Godwin AK, Yeung AT. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics. 2008 May;5(3-4):137-49.
Sanborn RE, Lally BE. Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement. Thorac Surg Clin. 2008 Nov;18(4):423-35.
Serebriiskii I, Castello-Cros R, Lamb A, Golemis EA, Cukierman E. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix biology : journal of the International Society for Matrix Biology. 2008 Jul;27(6):573-85.   PMCID: PMC2603546
Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92.   PMCID: PMC2448846
Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F, National Comprehensive Cancer N. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008 Apr;6(4):356-421.
Ariazi EA, Leitao A, Oprea TI, Chen B, Louis T, Bertucci AM, Sharma CG, Gill SD, Kim HR, Shupp HA, Pyle JR, Madrack A, Donato AL, Cheng D, Paige JR, Jordan VC. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol Cancer Ther. 2007 Nov;6(11):2817-27.
Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2007 Nov;7(7):650-65.
Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. The Prostate. 2007 May;67(6):582-90.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Litwin S, Wong YN, Hudes G. Early stopping designs based on progression-free survival at an early time point in the initial cohort. Statistics in medicine. 2007 Oct 30;26(24):4400-15.
Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10;24(26):4324-32.
Narra K, Borghaei H, Al-Saleem T, Hoglund M, Smith MR. Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature. Leukemia Research. 2006 Jan;30(1):109-14.
Ozols RF, Bookman MA, du Bois A, Pfisterer J, Reuss A, Young RC. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel. Gynecol Oncol. 2006 Oct;103(1):1-6.
Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9.
Tarn C, Godwin AK. The molecular pathogenesis of gastrointestinal stromal tumors . Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S7-17.
von Mehren M. Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies. Current oncology reports. 2006 May;8(3):192-7.
Wetherbee SL. New weapons to snuff out kidney cancer. Nursing. 2006 Dec;36(12 Pt.1):58-63; quiz 64.
Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Molecular Cancer Therapeutics. 2005 Mar;4(3):351-60.
Held-Warmkessel J. Managing three critical cancer complications. Nursing. 2005 Jan;35(1):58-63; quiz 63-4.
Manne SL, Ostroff JS, Winkel G, Fox K, Grana G, Miller E, Ross S, Frazier T, Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A, Morrow M, Chen JQ, Yager JD, Russo J, Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ, Devlin J, Sherman E, Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR, Murphy ME, Langer CJ, Mehta MP, Viterbo R, Greenberg RE, Al-Saleem T, Canutescu AA, Dunbrack RL, Serebriiskii IG, Fang R, Latypova E, Hopkins R, Vinson C, Joung JK, Golemis EA. Couple-focused group intervention for women with early stage breast cancer. . J Consult Clin Psychol. 2005 Sep 15;73(4):634-46.
Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clinical Colorectal Cancer. 2005 Jul;5(2):108-13.
Tarn C, Godwin AK. Molecular research directions in the management of gastrointestinal stromal tumors. Current treatment options in oncology. 2005 Nov;6(6):473-86.
Berger AC, Watson JC, Ross EA, Zalatoris A, Hoffman JP. Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma. Am Surg. 2004 Feb;70(2):169-73; discussion 173-4.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Einarson MB, Cukierman E, Compton DA, Golemis EA. Human enhancer of invasion-cluster, a coiled-coil protein required for passage through mitosis. Molecular and Cellular Biology. 2004 May;24(9):3957-71.
Langer CJ. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys. 2004 Mar;58(3):991-1002.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clinical lung cancer. 2004 Dec;6 Suppl 2:S85-8.
Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Ursulic S, Smyth J. Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer. 2003 Sep;39(13):1818-27.
Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003 Apr;21(7):1301-6.
Colice GL, Rubins J, Unger M. Follow-up and surveillance of the lung cancer patient following curative-intent therapy. Chest. 2003 Jan;123(1 Suppl):272S-283S.
Cortellino S, Turner D, Masciullo V, Schepis F, Albino D, Daniel R, Skalka AM, Meropol NJ, Alberti C, Larue L, Bellacosa A. The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A. 2003 Dec 09;100(25):15071-6.   PMCID: PMC299910
Eisenberg BL. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors. Oncology (Huntingt). 2003 Nov;17(11):1615-20; discussion 1620, 1623, 1626 passim.
Eisenberg BL, von Mehren M. Pharmacotherapy of gastrointestinal stromal tumours. Expert Opin Pharmacother. 2003 Jun;4(6):869-74.
Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study. Clin Cancer Res. 2003 Jan;9(1):109-14.
Jett JR, Scott WJ, Rivera MP, Sause WT. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest. 2003 Jan;123(1 Suppl):221S-225S.
Meyers MO, Sasson AR, Sigurdson ER. Locoregional strategies for colorectal hepatic metastases. Clin Colorectal Cancer. 2003 May;3(1):34-44.
Murphy ME. The thousand doors that lead to death: p53-dependent repression and apoptosis. Cancer Biol Ther. 2003 Jul;2(4):381-2.
Townsend D, Tew K. Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am J Pharmacogenomics. 2003 Jan;3(3):157-72.
Treat J. Weekly topotecan in the management of lung cancer. Lung Cancer. 2003 Aug;41 Suppl 4:S27-31.
Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, Jablonski SA, Hurle MR, Zhu Y, Yen TJ, Zhou BB. Chfr regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res. 2002 Mar 15;62(6):1797-801.
Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ. Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol. 2002 Jan;20(1):153-9.
Crul M, de Klerk GJ, Swart M, Weiner L, Palmer PA, Bol CJ, Beijnen JH, Schellens JH. Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors. Eur J Drug Metab Pharmacokinet. 2002 Jan;27(1):61-5.
Davey MP. Cancer treatments. Imatinib mesylate. Clinical Journal of Oncology Nursing. 2002 Mar;6(2):118-20.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England journal of medicine. 2002 Aug 15;347(7):472-80.
Entwistle JW, Goldberg M. Multimodality therapy for resectable cancer of the thoracic esophagus. Ann Thorac Surg. 2002 Mar;73(3):1009-15.
Held-Warmkessel J. What your patient needs to know about prostate cancer. Nursing. 2002 Dec;32(12):36-42; quiz N232.
Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36.
Hudes G. Boosting bioavailability of topotecan: what do we gain?. J Clin Oncol. 2002 Jul;20(13):2918-9.
Kim S, Domon-Dell C, Wang Q, Chung DH, Di Cristofano A, Pandolfi PP, Freund JN, Evers BM. PTEN and TNF-alpha regulation of the intestinal-specific Cdx-2 homeobox gene through a PI3K, PKB/Akt, and NF-kappaB-dependent pathway. Gastroenterology. 2002 Oct;123(4):1163-78.
Langer CJ. Elderly patients with lung cancer: biases and evidence. Current treatment options in oncology. 2002 Feb;3(1):85-102.
Ma J, Reed KA, Gallo JM. Cells designed to deliver anticancer drugs by apoptosis. Cancer Res. 2002 Mar;62(5):1382-7.
Ozols RF. Future directions in the treatment of ovarian cancer. Semin Oncol. 2002 Feb;29(1 Suppl 1):32-42.
Pan ZZ, Bruening W, Giasson BI, Lee VM, Godwin AK. Gamma-synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways. The Journal of biological chemistry. 2002 Sep 20;277(38):35050-60.
Roberts JD, Smith MR, Feldman EJ, Cragg L, Grant S. Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2002 Dec;3(3):184-8.
Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002 Jun 15;20(12):2895-903.
Shen M, Schilder RJ, Obasaju C, Gallo JM. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol. 2002 Sep;50(3):243-50.
Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, Pfister D, Sherman E, Goberdhan A, Hoffman RM, Shah J. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head & neck. 2002 May;24(5):437-42.
Babb JS, Rogatko A. Patient specific dosing in a cancer phase I clinical trial. Statistics in medicine. 2001 Jul 30;20(14):2079-90.
Bast RC, Mills GB, Young RC. Translational research--traffic on the bridge. Biomed Pharmacother. 2001 Nov;55(9-10):565-71.
Chen ZS, Aoki S, Komatsu M, Ueda K, Sumizawa T, Furukawa T, Okumura H, Ren XQ, Belinsky MG, Lee K, Kruh GD, Kobayashi M, Akiyama S. Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. International journal of cancer. 2001 Jul;93(1):107-13.
Cornfeld MJ, Jadwin A, O'Grady P, Babb J, Engstrom PF. Feasibility of assessing quality in medical oncology practices. Cancer Pract. 2001 Sep;9(5):231-5.
Davis W, Ronai Z, Tew KD. Cellular thiols and reactive oxygen species in drug-induced apoptosis. The Journal of pharmacology and experimental therapeutics. 2001 Jan;296(1):1-6.
Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 2001 Jan;7(1):153-7.
Langer CJ. The emerging world role of irinotecan in lung cancer. Oncology (Huntingt). 2001 Jul;15(7 Suppl 8):15-21.
Langer CJ. The role of UFT and the combination of UFT/leucovorin in non-small cell lung cancer. Lung Cancer. 2001 Nov;34(2):297-303.
Langer CJ. Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan. Oncology (Huntingt). 2001 Jan;15(1 Suppl 1):19-24.
Murphy BA, Leong T, Burkey B, Langer C, Forastiere A. Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393). Am J Clin Oncol. 2001 Feb;24(1):64-6.
O'Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson AB. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol. 2001 May;19(9):2413-21.
Ranganathan S, McCauley RA, Dexter DW, Hudes GR. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells. Br J Cancer. 2001 Sep;85(5):735-40.
Sasson AR, Hoffman JP, Ross E, Meropol NJ, Szarka CE, Freedman G, Pinover W, Pingpank JF, Eisenberg BL. Trimodality therapy for advanced gallbladder cancer. Am Surg. 2001 Mar;67(3):277-83; discussion 284.
Shen H, Chen ZJ, Zilfou JT, Hopper E, Murphy M, Tew KD. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. The Journal of pharmacology and experimental therapeutics. 2001 Jun;297(3):1067-73.
Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res. 2001 Oct;7(10):3251-7.
Von Roenn JH, Cianfrocca M. Treatment of Kaposi's sarcoma. Cancer Treat Res. 2001 Jan;104:127-48.
Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001 Sep;22(9):1379-83.
Baselli EC, Greenberg RE. Intravesical therapy for superficial bladder cancer. Oncology (Huntingt). 2000 May;14(5):719-29; discussion 729-31, 734, 737.
Bookman MA, Blessing JA, Hanjani P, Herzog TJ, Andersen WA. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2000 Jun;77(3):446-9.
Chu J, Gallo JM. Application of microdialysis to characterize drug disposition in tumors. Adv Drug Deliv Rev. 2000 Dec 15;45(2-3):243-53.
Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochemical pharmacology. 2000 Nov;60(9):1305-13.
Fowble B, Hanlon A, Freedman G, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Torosian M, Goldstein L. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer. Int J Radiat Oncol Biol Phys. 2000 Jul;47(4):883-94.
Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD. Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol. 2000 Jun;18(12):2459-67.
Langer CJ. The role of new agents in advanced non-small-cell lung carcinoma. Current oncology reports. 2000 Jan;2(1):76-89.
Lee K, Klein-Szanto AJ, Kruh GD. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. Journal of the National Cancer Institute. 2000 Dec 06;92(23):1934-40.
Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. Cancer Res. 2000 Oct;60(19):5390-4.
Schwartz AL, Nail LM, Chen S, Meek P, Barsevick AM, King ME, Jones LS. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest. 2000 Jan;18(1):11-9.
Young RC. The sounds of silence. Nature. 2000 Nov 09;408(6809):141.
Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. The oncologist. 1999 Jan;4(2):87-94.
Ozols RF. Oncology: current trends in the treatment of advanced ovarian cancer. Journal of Care Management. 1999 Aug;5(4):Disease Manage Digest: 6-7.
Dresler CM. Kidney metastases. Chest Surg Clin N Am. 1998 Feb;8(1):127-9.
Sokol DB, Hudes GR. Cisplatin-based chemotherapy for testicular cancer in a patient with spinal muscular atrophy: a case report. Am J Clin Oncol. 1998 Aug;21(4):420-1.
Tew KD, O'Brien M, Laing NM, Shen H. Coordinate changes in expression of protective genes in drug-resistant cells. Chem Biol Interact. 1998 Apr 24;111-112:199-211.
Fowble B. Postmastectomy radiation: then and now. Oncology (Huntingt). 1997 Feb;11(2):213-34, 239; discussion 239-40, 243.
Zhang X, Minale L, Zampella A, Smith CD. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides. Cancer Res. 1997 Sep;57(17):3751-8.
Martin V. Ovarian cancer: an update on new directions in screening and treatment. Journal of Gynecologic Oncology Nursing. 1996 Jan;6(3):9-11.
Martin VR. On the horizon. Clinical review of docetaxel (TAXOTERE). Innovations in Breast Cancer Care. 1996 Oct;2(1):9-12.
Martin VR, Comis RL. Small cell carcinoma of the lung: an "updated" overview. Seminars in Oncology Nursing. 1996 Nov;12(4):295-303.
Hoier H, Carrell HL, Glusker JP, Spears CP. Structure of ethyl phenyl selenone. Acta Crystallogr C. 1993 Mar 15;49 ( Pt 3):520-3.
Rogers BB. Taxol: a promising new drug of the '90s. Oncology Nursing Forum. 1993 Nov;20(10):1483-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Antineoplastic Agents

Antineoplastic Agents therapeutic use drug therapy Female Male Human pathology pharmacology metabolism Aged Middle Aged Adult drug effects adverse effects administration & dosage antagonists & inhibitors genetics therapy methods Neoplasms Monoclonal Antibodies US Gov't Support-PHS Lung Neoplasms 80 and over Aged Treatment Outcome mortality Disease-Free Survival Non-Small-Cell Lung Carcinoma Tumor Cell Line Non-US Gov't Support physiology Ovarian Neoplasms Mice Neoplasm Staging Cisplatin Neoplasm Drug Resistance pharmacokinetics Kidney Neoplasms Antineoplastic Combined Chemotherapy Protocols secondary Middle Age United States Prognosis surgery Apoptosis Immunotherapy Renal Cell Carcinoma dt [Drug Therapy] Drug Administration Schedule Protein Kinase Inhibitors Survival Rate analogs & derivatives Pyrimidines Drug Dose-Response Relationship Combined Modality Therapy Time Factors chemistry Paclitaxel Cultured Tumor Cells Neoplasm Metastasis Piperazines Squamous Cell Carcinoma diagnosis Clinical Trials Signal Transduction Survival Analysis 0 (Antineoplastic Agents) immunology Local Neoplasm Recurrence Cell Proliferation Cell Survival Neoplastic Gene Expression Regulation Retrospective Studies Adjuvant Chemotherapy Antitumor Drug Screening Assays blood Breast Neoplasms Neoadjuvant Therapy Prostatic Neoplasms chemically induced Head and Neck Neoplasms Adenocarcinoma Oral Administration Taxoids Kaplan-Meier Estimate Follow-Up Studies Clinical Trials as Topic epidemiology Molecular Targeted Therapy Animal Neoplasm Proteins enzymology Gastrointestinal Stromal Tumors Radiotherapy etiology radiotherapy Proportional Hazards Models Topotecan Medical Oncology Drug Delivery Systems Adolescent Intravenous Infusions Epidermal Growth Factor Receptor biosynthesis ae [Adverse Effects] Doxorubicin Pyrroles complications cytology Urinary Bladder Neoplasms Mutation Colorectal Neoplasms Maximum Tolerated Dose economics tu [Therapeutic Use] Molecular Models analysis trends Neoplasm Invasiveness dosage Young Adult Monoclonal Antibodies-Humanized Drug Synergism Indoles Enzyme Inhibitors Chemoradiotherapy Adjuvant Radiotherapy Fibroblasts Phytogenic Antineoplastic Agents Cell Cycle Proteins DNA Damage Biological Tumor Markers Gastrointestinal Neoplasms Combination Drug Therapy Radiotherapy Dosage ad [Administration and Dosage] Randomized Controlled Trials Oncologic Nursing DNA Repair Age Factors Molecular Sequence Data agonists Molecular Structure Disease Progression Drug Monitoring Androgen Antagonists US Gov't Support-Non-PHS me [Metabolism] Thiazoles Camptothecin
Last updated on Wednesday, March 04, 2020